New sunscreen ingredient wins FDA approval after 20 years

The long wait for bemotrizinol in U.S. sunscreens was driven far more by how the FDA regulates sunscreen than by any real doubt about the ingredient’s safety or usefulness.

Key Points

Bemotrizinol is a broad‑spectrum, photostable UV filter with an unusually robust safety record, now deemed “generally recognized as safe and effective” (GRASE) for people 6 months and older.^[3]^[6]
The ingredient was used for more than two decades in Europe, Asia, and other markets before U.S. approval, underscoring that the delay was regulatory, not a newly discovered hazard.^[1]^[4]
In the U.S., sunscreens are regulated as over‑the‑counter drugs, and decades of bureaucratic bottlenecks meant no new filters cleared the system from the late 1990s until bemotrizinol.
Bemotrizinol became the first sunscreen active ever approved via the streamlined OTC Monograph Order pathway created by the 2020 CARES Act, showing that process reform—not new science—finally unlocked its authorization.^[3]^[6]

What bemotrizinol is and why dermatologists care

To understand why the bemotrizinol story matters, start with what the molecule actually does. Bemotrizinol (also known as BEMT or bis‑ethylhexyloxyphenol methoxyphenyl triazine) is an organic UV filter that absorbs both UVA and UVB radiation, providing genuine broad‑spectrum coverage.^[4] Unlike several legacy U.S. filters that excel mainly at UVB (burn) protection, bemotrizinol has strong absorption in the longer‑wavelength UVA range that drives much of photoaging and contributes to skin cancer risk.^[4]

Two features make it particularly attractive. First, it is highly photostable: it does not rapidly break down under sunlight, which helps the protection last longer on the skin.^[1]^[4] Second, its molecule is relatively large and lipophilic, so in pharmacokinetic studies it shows very low systemic absorption—rarely exceeding the FDA’s threshold of 0.5 ng/mL in plasma at 6% concentration—while producing only mild, mostly trivial side effects. Dermatologists and toxicologists therefore regard it as both effective and, as far as current evidence goes, unusually safe.

Why the rest of the world got bemotrizinol decades earlier

The striking part of the story is not that bemotrizinol is effective; it is that Americans had to wait roughly a quarter century for a filter that had already become routine in European and Asian products. Bemotrizinol entered the European market around 2000 under trade names like Tinosorb S and later Parsol Shield, and it has been used continuously across Europe, Asia, Australia, and Latin America since then.^[4]^[5] Over those decades, no major safety crisis emerged. Instead, the accumulating dossier—animal toxicology, reproductive studies, irritation testing, and real‑world exposure—produced, in the view of some analysts, the most comprehensive safety data set of any modern UV filter.^[4]

The explanation for the timing gap lies not in chemistry but in classification. In the European Union, sunscreens are regulated as cosmetics; in the United States, they are regulated as over‑the‑counter (OTC) drugs. That single policy choice pushed new U.S. UV filters into a far more demanding pathway, akin to drug approval, even when the functional goal was the same: reducing UV damage in otherwise healthy people.

Inside the FDA’s process: how a safe ingredient can wait 20+ years

Historically, the FDA relied on the OTC “monograph” system, a kind of recipe book specifying which active ingredients, doses, and formats are considered GRASE and can be marketed without individual drug approvals. For sunscreens, the operative rules came from a long‑stalled 1999 monograph and a 2011 labeling and effectiveness rule. Under that regime, any new UV filter had to move through a cumbersome Time and Extent Application process and then await agency action that often did not come.

Bemotrizinol exemplifies that bottleneck. Industry submitted data, but the application lingered for years as the FDA cited limited resources and questions about data sufficiency.^[5] Meanwhile, other concerns about legacy filters—particularly evidence of higher systemic absorption for certain older actives—led the FDA in 2019 to ask for more safety information across the category, further slowing the queue. The net effect was paradoxical: the agency scrutinized existing ingredients more closely while providing no regulatory path for newer, potentially safer filters already vetted abroad. This changed only when Congress passed the CARES Act in 2020, which overhauled OTC drug regulation.

Bemotrizinol became the first sunscreen ingredient to use this modernized route. DSM Nutritional Products filed an OMOR in September 2024; the FDA issued a proposed order in December 2025; a 45‑day public comment period followed; and the final order adding bemotrizinol to the sunscreen monograph was issued in mid‑2026—about seven months after the proposal.^[3] For an OTC drug‑class ingredient, that turnaround is relatively brisk, and it underscores a key point: once a functioning procedural pathway existed, the science on bemotrizinol was sufficient to support approval.

What bemotrizinol means for people choosing sunscreen

For consumers and clinicians, the practical question is what changes now that bemotrizinol is on the U.S. market. First, it expands the toolkit. Bemotrizinol’s broad‑spectrum and photostable profile means formulators can achieve strong UVA and UVB protection with fewer trade‑offs in texture and white cast than mineral‑only products.^[1]^[4] That matters for adherence: the most protective sunscreen is the one people will actually apply liberally and reapply.

Second, its low systemic absorption offers an appealing option for those concerned about blood levels of older filters. FDA and independent researchers have documented that some legacy actives persist in the bloodstream for days after application, findings that, while not proving harm, have generated calls for more data. Bemotrizinol’s pharmacokinetic profile and long overseas track record give dermatologists a scientifically grounded answer when patients ask for a “safer chemical sunscreen.”^[2]^[4]

Third, approval does not mean instant shelf saturation. Formulating, stability testing, scaling production, and distributing new products takes time; early reports suggest the first bemotrizinol‑containing sunscreens will reach U.S. shelves roughly one to two years after the final order, with one supplier enjoying an 18‑month period of marketing exclusivity under the trade name Parsol Shield.^[3]^[4]^[5] In the meantime, the core behavioral advice does not change: daily use of a broad‑spectrum SPF 30 or higher product, applied generously and reapplied every two hours with continued sun exposure, remains the foundation of UV risk reduction.